# Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06795412/  
OnCo record `nct06795412` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Pyxis Oncology, Inc, now recruiting.

## Summary

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06795412 by Pyxis Oncology, Inc, with 220 participants planned, started 2025-04-15 and due to reach its primary completion in 2027-12-06. Interventions recorded: PYX-201 and pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06795412
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- Sponsor: Pyxis Oncology, Inc
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT06795412: https://clinicaltrials.gov/study/NCT06795412

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06795412.json